Clinical Trials – Page 5

Syndeio Biosciences Appoints Aaron Koenig, M.D., as Chief Medical Officer (CMO)

1 month ago talkbio0Tagged Aaron Koenig, Alzheimer 's disease, Chief Medical Officer, Clinical Trials, CNS disorder, neuropsychiatric, neuroscience drug development, synaptic health, Syndeio Biosciences, zelquistinel

Syndeio Biosciences; Aaron Koenig; Chief Medical Officer; CNS disorders; synaptic health; neuroscience drug development; zelquistinel; Alzheimer’s disease; neuropsychiatric; clinical trials

uniQure Faces Delay as FDA Walks Back Accelerated Approval for Huntington’s Gene Therapy

1 month ago talkbio0Tagged Accelerated, AMT-130, Approved, Clinical Trials, gene therapy, Huntington 's disease, Regulatory Setback, UniQure, United States Food and Drug Administration

uniQure; AMT-130; Huntington’s disease; gene therapy; FDA; accelerated approval; regulatory setback; clinical trial

Dyne Therapeutics’ z-rostudirsen Shows Durable Efficacy, Supporting Positive Regulatory Outlook

2 months ago talkbio0Tagged Accelerated, Approved, Biological Markers, Clinical Trials, DELIVER (veterinary product), Dyne Therapeutics, Effectiveness, Functional improvement, Muscular Dystrophy, Duchenne, regulatory approval, z-rostudirsen

Dyne Therapeutics; z-rostudirsen; DELIVER trial; Duchenne muscular dystrophy (DMD); durable efficacy; regulatory approval; biomarkers; functional improvement; accelerated approval

Wave Life Sciences Obesity Biomarker Data Raise Hopes for Future Readouts

2 months ago talkbio0Tagged Activin E :* *, Biological Markers, Body Composition, Clinical Trials, INHBE gene, INLIGHT trial, Obesity, RNA therapeutics, RNA, Small Interfering, Wave Life Sciences, Weight Loss, WVE-007

Wave Life Sciences; WVE-007; obesity; biomarker data; siRNA; Activin E; INHBE gene; RNA therapeutics; clinical trial; body composition; weight loss; INLIGHT trial

Viking Therapeutics to Highlight VK2735 Clinical Data at ObesityWeek 2025

2 months ago talkbio0Tagged Clinical Data, Clinical Trials, GLP-1/GIP Dual Agonist, Metabolic Syndrome X, Obesity, ObesityWeek 2025, Prediabetes syndrome, VANQUISH-1, venture, Viking Therapeutics, VK2735

Viking Therapeutics; VK2735; ObesityWeek 2025; VENTURE trial; VANQUISH-1 trial; GLP-1/GIP dual agonist; clinical data; obesity; prediabetes; metabolic syndrome

Eli Lilly and Nvidia to Build Pharma’s Largest AI Supercomputer for Drug Discovery

2 months ago talkbio0Tagged Artificial Intelligence, biomedical foundation models, Blackwell Ultra GPU, Clinical Trials, Drug Discovery, Drug Industry, eli lilly, high-performance computing, NVIDIA, supercomputer

Eli Lilly; Nvidia; supercomputer; AI; drug discovery; Blackwell Ultra GPU; clinical trials; biomedical foundation models; pharmaceutical industry; high-performance computing

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

2 months ago talkbio0Tagged Clearmind Medicine, Clinical Trials, governmental engagement, Mary-Elizabeth, mental health, partnerships, psychedelic medicine, regulatory advocacy, U.S.

Clearmind Medicine; Mary-Elizabeth Gifford; Chief of Global Impact; psychedelic medicine; US partnerships; governmental engagement; regulatory advocacy; biotech company; clinical trials; mental health

Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

2 months ago talkbio0Tagged AACR-NCI-EORTC, ARID1A mutation, Clinical Trials, Edison Oncology, Molecular Targets, Orotecan, ovarian neoplasm, OXPHOS pathway, Phase 1 - 2a, VAL-413

Edison Oncology; 2025 AACR-NCI-EORTC; Molecular Targets; Cancer Therapeutics; VAL-413; Orotecan; EO3001; ARID1A mutation; ovarian cancer; Phase 1-2a clinical trial; OXPHOS pathway

Unlocking Japan’s Potential in Rare Disease Drug Development: Recent Progress and Challenges (2025)

2 months ago talkbio0Tagged Clinical Trials, drug lag, Drugs, Orphan, innovation, Japan, pharmaceutical partnerships, Rare Diseases, regulatory approval

rare disease; Japan; orphan drug; drug lag; innovation; regulatory approval; pharmaceutical partnerships; clinical trials

Synbio International Inc. Expands Its Board of Directors and Strengthens Clinical Leadership

2 months ago talkbio0Tagged AI-driven, board of directors, Chief Financial Officer, Clinical Trials, Desiree Cain, Diagnostics, Nick Vatakis, Physician Executives, Synbio International Inc.

Synbio International Inc.; board of directors; Nick Vatakis; Desiree Cain; Medical Director; Chief Financial Officer; clinical trial; AI-driven diagnostics